Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics,...

Area of Science:

• Pediatric Rheumatology
• Immunology
• Genetics

Background:

• Macrophage activation syndrome (MAS) is a life-threatening complication of systemic juvenile idiopathic arthritis (sJIA), characterized by hemophagocytosis, coagulopathy, and organ dysfunction.
• Distinguishing MAS from sJIA flares is clinically challenging, necessitating improved diagnostic criteria.
• Genetic mutations in cytolytic pathways are increasingly linked to MAS development in sJIA patients.

Purpose of the Study:

• To review current understanding and diagnostic challenges of MAS in sJIA.
• To highlight the role of genetic mutations in MAS pathogenesis.
• To discuss the utility of novel murine models for studying MAS.

Main Methods:

• Review of literature on MAS in sJIA, including genetic studies and murine models.
• Analysis of a novel Toll-like receptor-stimulated mouse model of MAS.
• Evaluation of anti-cytokine therapies, specifically anti-interleukin-1, for MAS treatment.

Main Results:

• Mutations in cytolytic pathway genes are associated with MAS in sJIA.
• A new mouse model of MAS, independent of infection and triggered by Toll-like receptor stimulation, offers a relevant platform for studying autoinflammatory/autoimmune MAS.
• This model underscores the critical balance between pro- and anti-inflammatory cytokines.

Conclusions:

• Genetic insights and advanced murine models are crucial for advancing MAS diagnosis and understanding its pathophysiology.
• Targeted anti-cytokine therapies, particularly those inhibiting interleukin-1, show promise for treating MAS secondary to sJIA.